Fisons scraps anti-asthma drug
Wednesday 07 April 1993
The shares fell 25p to 169p after the company said it was stopping work on Tipredane, an anti-asthma and rhinitis steroid that has been undergoing clinical trials in several countries.
Cedric Scroggs, Fisons' chief executive, said the decision was a disappointment, but the drug, scheduled to be introduced commercially in 1997, had failed to prove sufficiently effective.
He said resources that would have been pumped into Tipredane would now go to fund a number of promising prospects, including new versions of Tilade, Fisons' latest anti-asthma product, and Remacemide.
Remacemide, an epilepsy treatment, is now Fisons' main new product hope but it is about a year behind Tipredane in trials and approvals.
Analysts said the abandonment of Tipredane was predictable as Glaxo had recently started marketing its own anti-asthma steroid, Flixotide. Tipredane would have been a late arrival, with no particular advantages over Flixotide and without Glaxo's marketing muscle.
'Fisons is a niche company at best,' said Robin Gilbert, an analyst with Panmure Gordon. 'Trying to get into big speculative markets five years out is not a wise course of action for it.'
Zeneca, the drugs side of ICI, said yesterday that it would accelerate development of Accolate, its new anti- asthma drug. Clinical testing should be complete by the end of 1994 and results from trials so far will be provided at the end of this month.
Is your name now 'banned' in Saudi Arabia?
Exclusive: World’s most pristine waters are polluted by US Navy human waste
Croatia's second city to close 'worst zoo in the world' after reports of 'nightmare' conditions and 'depressed' animals
Missing Malaysia Airlines Flight MH370: Did jetliner fly into area controlled by Taliban? Net widens after claims final satellite signal could have been sent from the ground
Missing Malaysia Airlines Flight MH370 Q&A by Simon Calder: How far could it have travelled? Who was responsible and what would their plans be? And how can a plane just vanish?
Katie Hopkins continues campaign to become Britain's most hated talking head with poorly timed Bob Crow tweet
Ukip and Nigel Farage on course for remarkable victory in European elections
No EU referendum under Labour: Ed Miliband to reveal that vote on membership is ‘unlikely’ in next Parliament if party wins power
Tony Benn was entirely ineffectual - and usually wrong
The rise of Ukip: Study warns Labour that Eurosceptic party's electoral base now 'more working class than any of the main parties'
Europeans have ‘got whiter’ due to natural selection in past 5,000 years, scientists say
- 1 Is your name now 'banned' in Saudi Arabia?
- 2 Gender-specific books demean all our children. So the Independent on Sunday will no longer review anything marketed to exclude either sex
- 3 Missing Malaysia Airlines Flight MH370 Q&A by Simon Calder: How far could it have travelled? Who was responsible and what would their plans be? And how can a plane just vanish?
- 4 California man Christopher Viatafa surrenders to police after googling own name and discovering himself listed as ‘most wanted’
- 5 'Missing Malaysia Airlines Flight MH370 plane found in Bermuda Triangle!' Viral Facebook links are profiting hackers
iJobs Money & Business
£35000 - £43000 per annum + Bonus and Benefits: Harrington Starr: A global lea...
£50000 - £60000 per annum: Harrington Starr: Linux Systems Administrator - UNI...
£32000 - £36000 per annum + generous benefits: Pro-Recruitment Group: * TAX * ...
£37000 - £40000 per annum + £20000 benefits package: Pro-Recruitment Group: **...